📇 Rhumatologue · CRETEIL CEDEX · (94) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
6 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
134 rhumatos / 100 000 hab. — département bien doté
4 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Influence scientifique
3
3 articles ont été cités au moins 3fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
15
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
4
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
0
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Paris-Est Créteil · Assistance Publique – Hôpitaux de Paris · Hôpitaux Universitaires Henri-Mondor
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Incidence and Mortality of Mucous Membrane Pemphigoid in France
2026ArticleBritish Journal of Dermatology
Cutaneous T-cell lymphomas and dupilumab use for atopic dermatitis: a systematic review and recommendations
2025CongrèsEORTC-Cutaneous-Lymphoma-Tumour-Group Annual Meeting
Increased risk of cutaneous squamous cell carcinomas in patients with Sézary syndrome: A nationwide multicenter retrospective study
2025ArticleJournal of The American Academy of Dermatology
Health products e‐sale should be regulated: a case of necrotizing soft‐tissue infection of the abdomen linked to self‐injection of slimming products purchased on the internet
2022ArticleInternational Journal of Dermatology
Éruptions eczématiformes chroniques du sujet âgé : quelle imputabilité médicamenteuse ?
2021ArticleAnnales de Dermatologie et de Vénéréologie - FMC
Pustular mycosis fungoides has a poor outcome: a clinico-pathological and longitudinal study of 36 cases
2021ArticleEuropean journal of cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP HM SITE HENRI MONDOR
51 AV MAL DE LATTRE DE TASSIGNY, 94010 CRETEIL CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Allergy · 2022
AbstractBackgroundCoronavirus disease‐2019 (COVID‐19) has been associated with cutaneous findings, some being the result of drug hypersensitivity reactions such as maculopapular drug rashes (MDR). The aim of this study was to investigate whether COVID‐19 may impact the development of the MDR.MethodsBlood and skin samples from COVID‐19 patients (based on a positive nasopharyngeal PCR) suffering from MDR (COVID‐MDR), healthy controls, non‐COVID‐19—related patients with drug rash with eosinophilia and systemic symptoms (DRESS), and MDR were analyzed. We utilized imaging mass cytometry (IMC) to characterize the cellular infiltrate in skin biopsies. Furthermore, RNA sequencing transcriptome of skin biopsy samples and high‐throughput multiplexed proteomic profiling of serum were performed.ResultsIMC revealed by clustering analyses a more prominent, phenotypically shifted cytotoxic CD8+T cell population and highly activated monocyte/macrophage (Mo/Mac) clusters in COVID‐MDR. The RNA sequencing transcriptome demonstrated a more robust cytotoxic response in COVID‐MDR skin. However, severe acute respiratory syndrome coronavirus 2 was not detected in skin biopsies at the time point of MDR diagnosis. Serum proteomic profiling of COVID‐MDR patients revealed upregulation of various inflammatory mediators (IL‐4, IL‐5, IL‐6, TNF, and IFN‐γ), eosinophil and Mo/Mac ‐attracting chemokines (MCP‐2, MCP‐3, MCP‐4 and CCL11).Proteomics analyses demonstrated a massive systemic cytokine storm in COVID‐MDR compared with the relatively milder cytokine storm observed in DRESS, while MDR did not exhibit such features.ConclusionA systemic cytokine storm may promote activation of Mo/Mac and cytotoxic CD8+T cells in severe COVID‐19 patients, which in turn may impact the development of MDR.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2023
AbstractBackgroundAdverse pregnancy outcomes (APO) occur in 35% of patients with pemphigoid gestationis (PG). No biological predictor of APO has been established yet.ObjectivesTo assess a potential relationship between the occurrence of APO and the serum value of anti‐BP180 antibodies at the time of PG diagnosis.MethodsMulticentre retrospective study conducted from January 2009 to December 2019 in 35 secondary and tertiary care centres. Inclusion criteria: (i) diagnosis of PG according to clinical, histological and immunological criteria, (ii) ELISA measurement of anti‐BP180 IgG antibodies determined at the time of PG diagnosis with the same commercial kit and (iii) obstetrical data available.ResultsOf the 95 patients with PG included, 42 had one or more APO, which mainly corresponded to preterm birth (n = 26), intrauterine growth restriction (IUGR) (n = 18) and small weight for gestational age at birth (n = 16). From a ROC curve, we identified a threshold of 150 IU ELISA value as the most discriminating to differentiate between patients with or without IUGR, with 78% sensitivity, 55% specificity, 30% positive and 91% negative predictive value. The threshold >150 IU was confirmed using a cross‐validation based on bootstrap resampling, which showed that the median threshold was 159 IU. Upon adjusting for oral corticosteroid intake and main clinical predictors of APO, an ELISA value of >150 IU was associated with the occurrence of IUGR (OR = 5.11; 95% CI: 1.48–22.30; p = 0.016) but not with any other APO. The combination of blisters and ELISA values higher than 150 IU led to a 2.4‐fold higher risk of all‐cause APO (OR: 10.90; 95% CI: 2.33–82.3) relative to patients with blisters but lower values of anti‐BP180 antibodies (OR of 4.54; 95% CI 0.92–34.2).ConclusionThese findings suggest that anti‐BP180 antibody ELISA value in combination with clinical markers is helpful in managing the risk of APO, in particular IUGR, in patients with PG.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of the American Academy of Dermatology · 2025 · Journal Article
Guillon L, Ram-Wolff C, Boulinguez S, Beylot-Barry M, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Journal Article
Cordel N, Flament J, Jouen F, Seta V, et al.
Allergy · 2022 · Journal Article
Mitamura Y, Schulz D, Oro S, Li N, et al.
European journal of cancer (Oxford, England : 1990) · 2021 · Journal Article
Galadari A, Ram-Wolff C, Al Hage J, De Masson A, et al.
European journal of cancer (Oxford, England : 1990) · 2021 · Journal Article
Badrignans M, Oro S, Chong-Si-Tsaon A, Bagny K, et al.
The British journal of dermatology · 2026 · Journal Article
Lefebvre A, Gillibert A, Tancrede-Bohin E, Loridon L, et al.